


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



12/15

Re the application of: Man Sung Co et al.

Serial No.: 09/249,011

Filed: February 12, 1999

For: *HUMANIZED IMMUNOGLOBULIN
REACTIVE WITH B7-2 AND METHODS OF
TREATMENT THEREWITH*

Attorney Docket No.: GNN-5315 (formerly GI-5315)

Group Art Unit: 1644

Examiner: P. Gambel

Assistant Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

November 6, 2000
Date of Signature and of Mail Deposit

By:

Megan E. Williams
Megan E. Williams, Ph.D.
Reg. No. 43,270
Agent for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their agent have become aware of the following publications and information, cited by the Examiner in the Office Action mailed October 10, 2000 (reference D1), and the publications cited in an International Search Report mailed September 5, 2000 during the prosecution of PCT/US00/03303 which

corresponds to the above referenced application. In accordance with 37 CFR §1.97(c)(1), Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon, except for reference D1 cited previously by the Examiner, are enclosed as well.


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(1), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

In the event that a final Office Action on the merits or a Notice of Allowance issues in this application bearing a mailing date prior to or the same date as the date of this Supplemental Information Disclosure Statement, please consider this a petition for the consideration of this Supplemental Information Disclosure Statement in accordance with 37 CFR §1.97(d)(2). Please charge the appropriate petition fee to our Deposit Order Account No. 120080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Megan E. Williams, Ph.D.
Registration No. 43,270
Agent for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: November 6, 2000

AEM/MEW/JKR/alf
Enclosures